An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

Dinh-Toi Chu*, Nguyen Duy Bac, Khanh Hoang Nguyen, Nguyen Le Bao Tien, Vo Van Thanh, Vu Thi Nga, Vo Truong Nhu Ngoc, Duong Thi Anh Dao, Le Ngoc Hoan, Nguyen Phuc Hung, Nguyen Thi Trung Thu, Van-Huy Pham, Le Nguyen Vu, Thuy Anh Vu Pham, Deepak B. Thimiri Govinda Raj

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

380 Downloads (Pure)


The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.
Original languageEnglish
Article number1822
JournalInternational Journal of Molecular Sciences
Issue number8
Number of pages17
Publication statusPublished - 2019


  • CD137/4-1BB
  • CD137L/4-1BBL
  • anti-CD137 antibodies
  • cancer immunotherapies
  • anti-CD137 antibody therapy
  • Biology (General)
  • QH301-705.5
  • Chemistry
  • QD1-999


Dive into the research topics of 'An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer'. Together they form a unique fingerprint.

Cite this